Cell2in is focusing on expanding the business in various ways.
Our platform technologies, products and experiences
will synergize in a collaborative work.

Cell2in is rapidly and efficiently maximizing its technical capabilities
through a global collaboration network with domestic and foreign experts and medical leading companies.

Global R&D

  • Cell therapeutics

    • Intractable Asthma
    • Osteoarthritis (OA)
    • Idiopathic pulmonary fibrosis (IPF)
    • Graft-versus-host disease (GvHD)
    • Multiple sclerosis (MS)
    • Cell therapy for pets
  • R&D Services

    • Cell quality evaluation technology
    • Antioxidant and anti-aging substance screening
    • Development of serum-free cell culture medium
    • Development of serum-free cryoprotectant
    • Mass production of customized stem cell culture medium
    • Production of high-quality extracellular vesicles and exosomes
    • Development of cell quality measuring device
  • Products

    • Cell quality management system: FreSHcell Q / FreSHtracer kit
    • Cells for therapyt & Customized cell culture medium
    • Exosome

Cell2in collaborative infrastructure

Global R&D

  • Stem cell therapy
    • Autologous stem cell and immunocyte efficacy evaluation and culture medium development

      T company

    • Stem cell culture and quality evaluation

      O company

    • Autologous stem cell and immunocyte quality evaluation

      H hospital, Japan

    • Hematopoietic stem cell quality evaluation

      C company, Israel

    • Diabetes treatment clinical trial donor cell therapy quality evaluation

      N company, Sweden

  • Exosome
    • Quality evaluation of stem cell-derived exosome of various uses

      O company and S company

    • Stem cell-derived exosome mass production and separation technology development

      R company, H company and R company

    • Stem cell-derived exosome for disease treatment mass production and separation technology development

      E company, Lithuania

  • Cell production quality control system
    • Injectable cell preservative and solution development

      E company, France

    • Cell mass culture quality control

      L company, Switzerland

    • Cell culture supplement medium development

      R company, Italy

    • Development of 3D Matrices for mass culture

      R company, Poland

    • Cell-customized chemical-defined culture medium development

      K company, Japan

    • Stem cell culture and quality evaluation

      Korea Institute of Radiological & Medical Sciences, Asan Medical Center, and Cha Medical Center


  • Professor
    Hyuk-soo Han
    • Seoul National University Orthopedic Clinic

      Clinical treatment of degenerative arthritis

  • Professor
    Hye-Ryun Kang
    • SNUH Department of Allergy and Clinical Immunology

      Clinical treatment of refractory asthma

  • Professor
    Sung-Soo Yoon
    • SNUH Department of Hemato Oncology

      Clinical treatment of GvHD and leukemia

  • Professor
    Jong Kwan Jun
    • SNUH Department of Obstetrics and Gynecology

      Research of stem cells including umbilical cord stem cells

  • Professor
    Jin-Woo Song
    • Asan Medical Center Department of Pulmonology

      Clinical treatment of idiopathic pulmonary fibrosis

  • Professor
    Hee-Myung Park
    • Konkuk University Veterinary Medical Teaching Hospital Veterinary Internal Medicine

      Multiple sclerosis treatment research

  • Director
    Jong-Il Kang
    • Choonghyun Animal Hospital

      Stem cell therapy animal disease clinical trials

Global Marketing

  • Ykio Takene
    • Former President of Sumitomo Bio

      Entrance of Japanese cell therapy market

  • Summer Park
    • Development director Pharma Ventures Ltd

      Transfer of European and foreign technologies